Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 21671877)

1.

The vanilloid agonist resiniferatoxin for interventional-based pain control.

Iadarola MJ, Mannes AJ.

Curr Top Med Chem. 2011;11(17):2171-9. Review.

2.
3.

Effect of resiniferatoxin on glutamatergic spontaneous excitatory synaptic transmission in substantia gelatinosa neurons of the adult rat spinal cord.

Jiang CY, Fujita T, Yue HY, Piao LH, Liu T, Nakatsuka T, Kumamoto E.

Neuroscience. 2009 Dec 29;164(4):1833-44. doi: 10.1016/j.neuroscience.2009.09.033. Epub 2009 Sep 22.

PMID:
19778582
4.

Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia.

Jeffry JA, Yu SQ, Sikand P, Parihar A, Evans MS, Premkumar LS.

PLoS One. 2009 Sep 15;4(9):e7021. doi: 10.1371/journal.pone.0007021.

5.

TRPV1, NK1 receptor and substance P immunoreactivity and gene expression in the rat lumbosacral spinal cord and urinary bladder after systemic, low dose vanilloid administration.

Heng YJ, Saunders CI, Kunde DA, Geraghty DP.

Regul Pept. 2011 Apr 11;167(2-3):250-8. doi: 10.1016/j.regpep.2011.02.004. Epub 2011 Feb 15.

PMID:
21329730
6.

Similar and different effects of capsaicin and resiniferatoxin on substance P release and transient receptor potential vanilloid type 1 expression of cultured rat dorsal root ganglion neurons.

Yang X, Gong H, Liu Z, Liu H, Wang H, Li Z.

Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):3-11. doi: 10.1358/mf.2010.32.1.1444424.

PMID:
20383340
7.

Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials.

Kissin I, Szallasi A.

Curr Top Med Chem. 2011;11(17):2159-70. Review.

PMID:
21671878
8.

Preservation of acute pain and efferent functions following intrathecal resiniferatoxin-induced analgesia in rats.

Bishnoi M, Bosgraaf CA, Premkumar LS.

J Pain. 2011 Sep;12(9):991-1003. doi: 10.1016/j.jpain.2011.03.005. Epub 2011 Jun 16.

9.

Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin.

Raisinghani M, Pabbidi RM, Premkumar LS.

J Physiol. 2005 Sep 15;567(Pt 3):771-86. Epub 2005 Jul 21.

10.

Human keratinocytes are vanilloid resistant.

Pecze L, Szabó K, Széll M, Jósvay K, Kaszás K, Kúsz E, Letoha T, Prorok J, Koncz I, Tóth A, Kemény L, Vizler C, Oláh Z.

PLoS One. 2008;3(10):e3419. doi: 10.1371/journal.pone.0003419. Epub 2008 Oct 14.

11.

Ablation of rat TRPV1-expressing Adelta/C-fibers with resiniferatoxin: analysis of withdrawal behaviors, recovery of function and molecular correlates.

Mitchell K, Bates BD, Keller JM, Lopez M, Scholl L, Navarro J, Madian N, Haspel G, Nemenov MI, Iadarola MJ.

Mol Pain. 2010 Dec 17;6:94. doi: 10.1186/1744-8069-6-94.

12.
13.

Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception.

Chen SR, Pan HL.

Neuropharmacology. 2008 Aug;55(2):215-22. doi: 10.1016/j.neuropharm.2008.05.011. Epub 2008 May 22.

14.

The glutamatergic nature of TRPV1-expressing neurons in the spinal dorsal horn.

Zhou HY, Chen SR, Chen H, Pan HL.

J Neurochem. 2009 Jan;108(1):305-18. doi: 10.1111/j.1471-4159.2008.05772.x. Epub 2008 Nov 19.

15.

Prolonged analgesic response of cornea to topical resiniferatoxin, a potent TRPV1 agonist.

Bates BD, Mitchell K, Keller JM, Chan CC, Swaim WD, Yaskovich R, Mannes AJ, Iadarola MJ.

Pain. 2010 Jun;149(3):522-8. doi: 10.1016/j.pain.2010.03.024. Epub 2010 Apr 18.

16.

Perineural resiniferatoxin selectively inhibits inflammatory hyperalgesia.

Neubert JK, Mannes AJ, Karai LJ, Jenkins AC, Zawatski L, Abu-Asab M, Iadarola MJ.

Mol Pain. 2008 Jan 16;4:3. doi: 10.1186/1744-8069-4-3.

17.

Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.

Ursu D, Knopp K, Beattie RE, Liu B, Sher E.

Eur J Pharmacol. 2010 Sep 1;641(2-3):114-22. doi: 10.1016/j.ejphar.2010.05.029. Epub 2010 Jun 8.

PMID:
20576527
18.

Vanilloid-induced conduction analgesia: selective, dose-dependent, long-lasting, with a low level of potential neurotoxicity.

Kissin I.

Anesth Analg. 2008 Jul;107(1):271-81. doi: 10.1213/ane.0b013e318162cfa3. Review.

19.

Targeting TRPV1 for pain relief: limits, losers and laurels.

Szallasi A, Sheta M.

Expert Opin Investig Drugs. 2012 Sep;21(9):1351-69. doi: 10.1517/13543784.2012.704021. Epub 2012 Jul 11. Review.

PMID:
22780443
20.

Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?

Knotkova H, Pappagallo M, Szallasi A.

Clin J Pain. 2008 Feb;24(2):142-54. doi: 10.1097/AJP.0b013e318158ed9e. Review.

PMID:
18209521
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk